Long-term clinical and radiological outcome of a cementless titanium-coated total knee arthroplasty system.

Nina Hörlesberger, Maria Anna Smolle, Lukas Leitner, Georg Hauer, Andreas Leithner, Patrick Sadoghi
Author Information
  1. Nina Hörlesberger: Department of Orthopaedics and Trauma, Medical University of Graz, Auenbruggerplatz 5, 8036, Graz, Austria.
  2. Maria Anna Smolle: Department of Orthopaedics and Trauma, Medical University of Graz, Auenbruggerplatz 5, 8036, Graz, Austria. maria.smolle@medunigraz.at.
  3. Lukas Leitner: Department of Orthopaedics and Trauma, Medical University of Graz, Auenbruggerplatz 5, 8036, Graz, Austria.
  4. Georg Hauer: Department of Orthopaedics and Trauma, Medical University of Graz, Auenbruggerplatz 5, 8036, Graz, Austria.
  5. Andreas Leithner: Department of Orthopaedics and Trauma, Medical University of Graz, Auenbruggerplatz 5, 8036, Graz, Austria.
  6. Patrick Sadoghi: Department of Orthopaedics and Trauma, Medical University of Graz, Auenbruggerplatz 5, 8036, Graz, Austria.

Abstract

INTRODUCTION: To ensure a high-quality standard, it is important to frequently evaluate different prostheses models to avoid prostheses with high failure rates. Thus, the aim of the study was to evaluate the long-term outcome of the uncemented titanium-coated total knee arthroplasty (TKA) system (Advanced Coated System (ACS) III, Implantcast, GERMANY). We hypothesized that the ACS III would have a similar performance as other cemented TKA systems.
MATERIALS AND METHODS: A total of 540 ACS III mobile-bearing knee joint prostheses were implanted in 495 patients. The visual analogue scale (VAS) score, Tegner activity score (TAS), knee society score (KSS), Western Ontario and McMaster (WOMAC) score, and the Short Form 12 (SF-12) score for the evaluation of quality of life (QoL) were taken after at least 9 years of follow-up. In addition, we measured range of motion (ROM) and assessed potential sex differences. In addition, the survival analysis was calculated at a median follow-up of 16.7 years.
RESULTS: At the final follow-up, 142 patients had died, and 38 had been lost to follow-up. The rate of revision-free implant survival at 16.7 years was 90.0% (95% CI 87.1-92.2%) and the rate of infection-free survival was 97.0% (IQR 95.2-98.2%). The reasons for revision surgery were aseptic loosening (32.9%), followed by infection (27.1%), inlay exchange (15.9%), and periprosthetic fractures (5.7%). At the clinical follow-up visit, the mean VAS score was 1.9 ± 1.9, the median TAS was 3 (IQR 2-4), and the mean KSS for pain and function were 83.5 ± 15.3 and 67.5 ± 25.2, respectively. The mean WOMAC score was 81.1 ± 14.9, and the median SF-12 scores for physical and mental health were 36.9 (IQR 29.8-45.1) and 55.8 (IQR 46.2-61.0), respectively. The mean knee flexion was 102.0° ± 15.4°. Male patients had better clinical outcome scores than female patients [SF-12 mental health score, p = 0.037; SF-12 physical health score, p = 0.032; KSS pain score (p < 0.001), and KSS functional score (p < 0.001)].
CONCLUSION: The ACS III TKA system is a suitable option for the treatment of end-stage osteoarthritis of the knee joint because of its adequate long-term survival. Our findings are in line with published data on similar TKA systems that have shown favourable clinical scores in males.
LEVEL OF EVIDENCE: Level III-Retrospective cohort study.

Keywords

References

  1. Int Orthop. 2014 Dec;38(12):2489-93 [PMID: 25027979]
  2. World J Orthop. 2018 Apr 18;9(4):60-64 [PMID: 29686970]
  3. Knee Surg Sports Traumatol Arthrosc. 2015 Jun;23(6):1833-40 [PMID: 25283502]
  4. Bone Joint J. 2021 Jan;103-B(1):18-25 [PMID: 33380199]
  5. Bone Joint J. 2018 May 1;100-B(5):579-583 [PMID: 29701098]
  6. SICOT J. 2017;3:70 [PMID: 29232186]
  7. J Arthroplasty. 2017 Jul;32(7):2161-2166 [PMID: 28285899]
  8. World J Orthop. 2017 Dec 18;8(12):922-928 [PMID: 29312851]
  9. Clin Orthop Relat Res. 2006 May;446:221-6 [PMID: 16672891]
  10. J Knee Surg. 2014 Oct;27(5):369-76 [PMID: 24318196]
  11. Arch Bone Jt Surg. 2013 Dec;1(2):48-52 [PMID: 25207287]
  12. J Bone Joint Surg Br. 1954 Nov;36-B(4):553-60 [PMID: 13211730]
  13. J Arthroplasty. 2018 Jul;33(7):2153-2158 [PMID: 29555496]
  14. Clin Orthop Relat Res. 2010 Jan;468(1):57-63 [PMID: 19844772]
  15. Clin Orthop Relat Res. 2011 Jul;469(7):1846-51 [PMID: 21267799]
  16. Indian J Orthop. 2022 Aug 22;56(10):1767-1773 [PMID: 36187581]
  17. Sci Rep. 2016 Apr 19;6:24630 [PMID: 27090945]
  18. J Arthroplasty. 2015 Dec;30(12):2164-6 [PMID: 26100473]
  19. J Arthroplasty. 2011 Jun;26(4):537-42 [PMID: 20634039]
  20. Arthroplast Today. 2017 Oct 21;4(1):94-98 [PMID: 29564376]
  21. J Bone Joint Surg Am. 2012 Sep 19;94(18):1681-4 [PMID: 22992879]
  22. Clin Orthop Surg. 2018 Mar;10(1):26-32 [PMID: 29564044]
  23. Biomaterials. 2006 Jun;27(18):3351-60 [PMID: 16488005]
  24. Ann Rheum Dis. 1973 Sep;32(5):397-405 [PMID: 4751775]
  25. Orthop Traumatol Surg Res. 2009 May;95(3):177-82 [PMID: 19328763]
  26. J Arthroplasty. 2013 Mar;28(3):390-4 [PMID: 23142436]
  27. Knee Surg Sports Traumatol Arthrosc. 2021 Mar;29(3):750-756 [PMID: 32367201]
  28. J Mater Sci Mater Med. 2017 Jul;28(7):105 [PMID: 28534290]
  29. J Bone Joint Surg Am. 2007 Apr;89(4):780-5 [PMID: 17403800]
  30. World J Surg. 2008 Jun;32(6):952 [PMID: 18401640]
  31. Int Orthop. 2017 Oct;41(10):2037-2044 [PMID: 28550426]
  32. Acta Orthop Belg. 2014 Jun;80(2):269-75 [PMID: 25090802]
  33. J Arthroplasty. 2013 Sep;28(8):1329-32 [PMID: 23602418]
  34. Sci Rep. 2018 Mar 16;8(1):4707 [PMID: 29549305]
  35. Clin Orthop Surg. 2017 Jun;9(2):169-176 [PMID: 28567218]
  36. BMJ Evid Based Med. 2018 Feb;23(1):23-24 [PMID: 29367322]
  37. SICOT J. 2023;9:5 [PMID: 36757220]
  38. Knee Surg Sports Traumatol Arthrosc. 2023 Mar;31(3):839-851 [PMID: 34714355]

MeSH Term

Humans
Male
Female
Arthroplasty, Replacement, Knee
Quality of Life
Titanium
Retrospective Studies
Knee Prosthesis
Knee Joint
Pain
Treatment Outcome
Osteoarthritis, Knee
Range of Motion, Articular

Chemicals

Titanium

Word Cloud

Created with Highcharts 10.0.0scorekneeACSIIIfollow-upTKApatientsKSSsurvivalIQRclinicalmeanprosthesesoutcometotalarthroplastysystemSF-12median9scoreshealthevaluatestudylong-termtitanium-coatedsimilarsystemsjointVASTASWOMACadditionanalysis167 yearsrate0%2%9%13painrespectivelyphysicalmentalp = 0p < 0001INTRODUCTION:ensurehigh-qualitystandardimportantfrequentlydifferentmodelsavoidhighfailureratesThusaimuncementedAdvancedCoatedSystemImplantcastGERMANYhypothesizedperformancecementedMATERIALSANDMETHODS:540mobile-bearingimplanted495visualanaloguescaleTegneractivitysocietyWesternOntarioMcMasterShortForm12evaluationqualitylifeQoLtakenleast9 yearsmeasuredrangemotionROMassessedpotentialsexdifferencescalculatedRESULTS:final142died38lostrevision-freeimplant9095%CI871-92infection-free97952-98reasonsrevisionsurgeryasepticloosening32followedinfection271%inlayexchange15periprostheticfractures57%visit9 ± 12-4function835 ± 15675 ± 252811 ± 1436298-45558462-610flexion1020° ± 15Malebetterfemale[SF-12037032functional]CONCLUSION:suitableoptiontreatmentend-stageosteoarthritisadequatefindingslinepublisheddatashownfavourablemalesLEVELOFEVIDENCE:LevelIII-RetrospectivecohortLong-termradiologicalcementlessOutcomeTin-coatedprosthesisTotal

Similar Articles

Cited By